Quest Diagnostics Pre-Tax Profit Margin 2010-2024 | DGX
Current and historical pre-tax profit margin for Quest Diagnostics (DGX) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Quest Diagnostics pre-tax profit margin for the three months ending September 30, 2024 was .
| Quest Diagnostics Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$9.54B |
$1.11B |
11.67% |
| 2024-06-30 |
$9.35B |
$1.12B |
11.94% |
| 2024-03-31 |
$9.29B |
$1.12B |
12.05% |
| 2023-12-31 |
$9.25B |
$1.13B |
12.21% |
| 2023-09-30 |
$9.30B |
$1.00B |
10.78% |
| 2023-06-30 |
$9.49B |
$1.05B |
11.11% |
| 2023-03-31 |
$9.60B |
$1.06B |
11.04% |
| 2022-12-31 |
$9.88B |
$1.24B |
12.50% |
| 2022-09-30 |
$10.29B |
$1.63B |
15.82% |
| 2022-06-30 |
$10.58B |
$1.93B |
18.25% |
| 2022-03-31 |
$10.68B |
$2.43B |
22.71% |
| 2021-12-31 |
$10.79B |
$2.60B |
24.09% |
| 2021-09-30 |
$11.05B |
$2.86B |
25.85% |
| 2021-06-30 |
$11.06B |
$2.95B |
26.71% |
| 2021-03-31 |
$10.34B |
$2.39B |
23.14% |
| 2020-12-31 |
$9.44B |
$1.88B |
19.96% |
| 2020-09-30 |
$8.36B |
$1.45B |
17.39% |
| 2020-06-30 |
$7.53B |
$0.97B |
12.89% |
| 2020-03-31 |
$7.66B |
$0.98B |
12.81% |
| 2019-12-31 |
$7.73B |
$1.08B |
13.93% |
| 2019-09-30 |
$7.64B |
$0.92B |
11.98% |
| 2019-06-30 |
$7.57B |
$0.91B |
12.03% |
| 2019-03-31 |
$7.54B |
$0.91B |
12.07% |
| 2018-12-31 |
$7.53B |
$0.93B |
12.30% |
| 2018-09-30 |
$7.56B |
$0.99B |
13.14% |
| 2018-06-30 |
$7.52B |
$0.99B |
13.09% |
| 2018-03-31 |
$7.47B |
$1.01B |
13.56% |
| 2017-12-31 |
$7.40B |
$1.03B |
13.92% |
| 2017-09-30 |
$7.10B |
$1.04B |
14.63% |
| 2017-06-30 |
$7.13B |
$1.07B |
15.00% |
| 2017-03-31 |
$7.17B |
$1.16B |
16.18% |
| 2016-12-31 |
$7.21B |
$1.09B |
15.05% |
| 2016-09-30 |
$7.50B |
$1.05B |
13.99% |
| 2016-06-30 |
$7.50B |
$1.35B |
18.04% |
| 2016-03-31 |
$7.52B |
$1.17B |
15.56% |
| 2015-12-31 |
$7.49B |
$1.10B |
14.72% |
| 2015-09-30 |
$7.53B |
$1.10B |
14.63% |
| 2015-06-30 |
$7.55B |
$0.72B |
9.57% |
| 2015-03-31 |
$7.53B |
$0.75B |
9.99% |
| 2014-12-31 |
$7.44B |
$0.82B |
11.07% |
| 2014-09-30 |
$7.31B |
$0.83B |
11.40% |
| 2014-06-30 |
$7.19B |
$1.28B |
17.74% |
| 2014-03-31 |
$7.11B |
$1.30B |
18.34% |
| 2013-12-31 |
$7.15B |
$1.32B |
18.53% |
| 2013-09-30 |
$7.16B |
$1.34B |
18.72% |
| 2013-06-30 |
$7.20B |
$0.96B |
13.27% |
| 2013-03-31 |
$7.26B |
$1.00B |
13.73% |
| 2012-12-31 |
$7.38B |
$1.07B |
14.47% |
| 2012-09-30 |
$7.37B |
$1.12B |
15.22% |
| 2012-06-30 |
$7.45B |
$1.13B |
15.21% |
| 2012-03-31 |
$7.48B |
$1.11B |
14.90% |
| 2011-12-31 |
$7.39B |
$0.85B |
11.49% |
| 2011-09-30 |
$7.35B |
$0.82B |
11.19% |
| 2011-06-30 |
$7.31B |
$0.85B |
11.64% |
| 2011-03-31 |
$7.28B |
$0.90B |
12.40% |
| 2010-12-31 |
$7.26B |
$1.18B |
16.20% |
| 2010-09-30 |
$7.39B |
$1.21B |
16.36% |
| 2010-06-30 |
$7.43B |
$1.23B |
16.50% |
| 2010-03-31 |
$7.45B |
$1.22B |
16.33% |
| 2009-12-31 |
$7.46B |
$1.23B |
16.47% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$17.320B |
$9.252B |
|
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
|
